TECENTRIQ HYBREZA Trademark
TECENTRIQ HYBREZA is a USPTO trademark filed by Genentech, Inc.. Status: Registered.
Prosecution Summary
Trademark Summary
TECENTRIQ HYBREZA is a standard character trademark covering pharmaceutical preparations applied subcutaneously and containing atezolizumab for the treatment of oncological disorders and diseases in class 005, with additional domestic classifications in classes 006, 018, 044, 046, 051, and 052. The mark is registered on the Principal Register (Reg. No. 7779001) effective April 29, 2025. It is owned by Genentech, Inc., a Delaware corporation located in South San Francisco, California. No oppositions or legal proceedings are present.
Recent Activity
The application was filed on March 30, 2022, published for opposition on May 30, 2023, and issued a Notice of Allowance on July 25, 2023. Following two extensions and a Statement of Use f
Trademark Facts
| Mark | TECENTRIQ HYBREZA |
|---|---|
| Serial Number | 97338550 |
| Registration Number | 7779001 |
| Status | Registered |
| Filing Date | 2022-03-30 |
| Registration Date | 2025-04-29 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Genentech, Inc. |
| Attorney of Record | Gregory Zinkl |
| Prosecution Events | 44 |
| Latest Event | COAR on 2026-04-09 |
Goods & Services
Pharmaceutical preparations, applied subcutaneously and containing atezolizumab, for the treatment of oncological disorders and diseases